GHRS
NASDAQ
IE
GH Research PLC - Ordinary Shares
$14.57
▼ $-0.15
(-1.02%)
Vol 103K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$787.8M
ROE
-15.8%
D/E
0.20
Beta
1.01
52W
$7–$21
Wall Street Consensus
15 analysts · Apr 20264
Strong Buy
10
Buy
1
Hold
0
Sell
0
Strong Sell
93.3%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 100.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.28 | $-0.23 | +$0.05 |
| Sep 2025 | $-0.24 | $-0.23 | +$0.01 |
| Jun 2025 | $-0.22 | $-0.15 | +$0.07 |
| Mar 2025 | $-0.40 | $-0.19 | +$0.21 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net Income | — | -$8.8M | -$10.8M | -$9.3M | -$14.0M | -$14.1M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -16.7% | -16.7% | -16.7% | -16.7% | -15.8% | -15.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.21 | 0.21 | 0.21 | 0.21 | 0.20 | 0.20 |
| Current Ratio | 29.49 | 29.49 | 29.49 | 29.49 | 28.32 | 28.32 |
Key Ratios
ROA (TTM)
-15.3%
P/B
2.0
EPS (TTM)
$-0.73
52W High
$20.50
52W Low
$6.85
$6.85
52-Week Range
$20.50
Financial Health
Free Cash Flow
-$12.3M
Net Debt
-$245.7M
Cash
$246.3M
Total Debt
$512K
As of Dec 31, 2025
How does GHRS compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
GHRS valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(5.0)
vs Peers
vs Industry
Overvalued
P/B ratio
2.0
▼
4%
below
peers
(2.1)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
GHRS profitability vs Pharmaceuticals peers
ROE
-15.8%
▲
71%
above
peers
(-54.3%)
vs Peers
vs Industry
Top tier
Net margin
—
▼
0%
below
peers
(-47.4%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(68.3%)
vs Peers
vs Industry
In line
ROA
-15.3%
▲
59%
above
peers
(-37.4%)
vs Peers
vs Industry
Below avg
GHRS financial health vs Pharmaceuticals peers
D/E ratio
0.2
▼
87%
below
peers
(1.5)
vs Peers
vs Industry
Above avg
Current ratio
28.3
▲
743%
above
peers
(3.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.0
▲
8%
above
peers
(0.9)
vs Peers
vs Industry
Less volatile
GHRS fundamentals radar
GHRS
Peer median
Industry
GHRS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
GHRS vs peers: key metrics
Top Holders
Top 5: 61.24%Lynx1 Capital Management Lp
16.78%
$136.8M
BVF Inc.
14.23%
$116.1M
RA Capital Management, L.P.
12.38%
$100.9M
RTW Investments LP
9.57%
$78.0M
FMR, LLC
8.28%
$67.5M
As of Dec 31, 2025
Latest News
No related news yet